Antiviral agents in Alzheimer’s disease: hope for the future?
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Alzheimer’s disease (AD) is characterized by loss of memory and intellectual function. It currently afflicts around 18 million people worldwide but the total numbers affected, if carers and relatives are included, are far greater. AD places enormous emotional and financial burdens on individuals and the state, and as more people are predicted to survive to old age, these burdens will increase if no effective treatment is discovered. AD is categorized by age of onset (early versus late onset) and by whether there is an inherited component to the disease (familial versus sporadic). Except for a small number of early-onset, familial AD cases that have a clear genetic component, the causes of AD are unclear, although risk factors for the disease are known and include increasing age, Down's syndrome, and possibly head injury. Accumulating evidence suggests that infectious agents are important etiological factors in AD. Superficially, infectious agents such as viruses and bacteria might not seem likely candidates as causes of chronic diseases. This is perhaps because microbes are generally known to be the cause of many acute illnesses, and so they are assumed to vanish or to be expunged from the body when the illness ends. However, this reasoning fails to take into account the ability of many micro-organisms to remain in a dormant state until certain events reawaken them to a virulent state. This process of dormancy followed by activation makes infectious agents prime candidates as factors in chronic diseases. Certainly, there are a number of major precedents for the correctness of such a ‘heretical’ concept, for example, viruses in various cancers, and the bacterium Helicobacter pylori in stomach ulcers [Marshall and Warren, 1984]. In the case of AD, several agents have been proposed but the focus of this review is the evidence for an involvement of herpes simplex virus type 1 (HSV1). The rationale for implicating HSV1, a neurotropic virus, in AD is based on several facts. First, initial infection with this virus usually occurs in infancy and once infected it remains lifelong in the peripheral nervous system (PNS) in a latent state. However, HSV1 can be reactivated repeatedly by events such as stress and immunosuppression, leading to a productive infection and virus replication, and in some people this results in herpes labialis (cold sores). Thus, if HSV1 were eventually to reach the brain, repeated reactivation of the virus there could lead to accumulation of damage, manifesting at a late stage in life, consistent with the onset of AD usually in older age. Second, the virus is ubiquitous, infecting about 90% of the adult population: a necessary characteristic in view of the high prevalence of AD. Finally, HSV1 causes a rare but severe brain disorder, herpes simplex encephalitis (HSE), and the main regions affected, the frontal and temporal cortices, are those showing the main pathological changes in AD; for these reasons, the virus was proposed as a likely candidate agent in AD [Ball, 1982]. Further, those who survive HSE usually suffer from memory loss and cognitive impairment [Hokkanen and Launes, 2000]. This review focuses on the questions that have been asked in order to investigate a possible role for HSV1 in AD (but omits descriptions of the virus lifecycle and of certain viral effects that may play a role, such as oxidation and autophagy, as they were discussed in a previous review [Itzhaki and Wozniak, 2008]). Further, it describes the use of current and of possible future antiviral agents.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Alzheimer's Disease-Associated Amyloid β-Protein Is an Antimicrobial Peptide
Soscia, S. J., Kirby, J. E., Washicosky, K. J., Tucker, S. M., Ingelsson, M., Hyman, B., Burton, M. A., Goldstein, L. E., Duong, S., Tanzi, R. E., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0009505 · Cited by 1,060 · cited 1×
“In fact, there is evidence that amyloid oligomers have bacteriostatic activity [R. Tanzi, personal communication; Soscia et al. 2010; Strobel, 2009].”
BackgroundHerpes simplex virus type 1 DNA is located within Alzheimer's disease amyloid plaques
Wozniak, M., Mee, A., & Itzhaki, R. (2009) · The Journal of Pathology · doi:10.1002/path.2449 · Cited by 464
Self-citationJi, Z. S., Brecht, W. J., Miranda, R. D., Hussain, M. M., Innerarity, T. L., & Mahley, R. W. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)82186-x · Cited by 305 · cited 2×
“…and several infectious diseases, is that they might compete for binding and entry at the cell membrane [Itzhaki et al. 1997b], where both virus and protein bind to heparan sulfate proteoglycans (HSPG) before attaching to specific receptors for cell entry [Ji et al. 1993; WuDunn and Spear, 1989].”
BackgroundLetenneur, L., Pérès, K., Fleury, H., Garrigue, I., Barberger-Gateau, P., Helmer, C., Orgogozo, J.-M., Gauthier, S., & Dartigues, J.-F. (2008) · PLoS ONE · doi:10.1371/journal.pone.0003637 · Cited by 252 · cited 2×
“A third study, which surveyed a group of people aged 65 over a 14-year period, suggests that those who experience HSV1 reactivation have an increased risk of developing AD [Letenneur et al. 2008].”
BackgroundChlamydia pneumoniae induces Alzheimer-like amyloid plaques in brains of BALB/c mice
Little, C. S., Hammond, C. J., MacIntyre, A., Balin, B. J., & Appelt, D. M. (2004) · Neurobiology of Aging · doi:10.1016/s0197-4580(03)00127-1 · Cited by 243
Anthony, I. C., Ramage, S. N., Carnie, F. W., Simmonds, P., & Bell, J. E. (2006) · Acta Neuropathologica · doi:10.1007/s00401-006-0037-0 · Cited by 158
Double stranded RNA activated EIF2 α kinase (EIF2AK2; PKR) is associated with Alzheimer's disease
Bullido, M. J., Martínez-García, A., Tenorio, R., Sastre, I., Muñoz, D. G., Frank, A., & Valdivieso, F. (2008) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2007.02.023 · Cited by 51
Cognitive Outcome in Acute Sporadic Encephalitis
Hokkanen, L., & Launes, J. (2000) · Neuropsychology Review · doi:10.1023/a:1009079531196 · Cited by 49 · cited 2×
“…of Manchester, Oxford Road, Manchester M13 9PT, UK ruth.itzhaki@ manchester.ac.uk Matthew A. Wozniak, BSc, PhD 3.614 Stopford Building, Faculty of Life Sciences, The University of Manchester, Oxford Road, Manchester M13 9PT, UK from memory loss and cognitive impairment [Hokkanen and Launes, 2000].”
BackgroundInfluential
Cited by
The preclinical phase of the pathological process underlying sporadic Alzheimer’s disease
Braak, H., & Del Tredici, K. (2015) · Brain · doi:10.1093/brain/awv236 · Cited by 540
“…a potential danger and possibly not only hyperphosphorylate tau but also induce a conformational change in the protein (Ball, 1982; Jamieson et al., 1991; Wozniak et al., 2009a; Itzhaki and Wozniak, 2010; Wozniak and Itzhaki, 2010; Deruelle and Favoreel, 2011; Ball et al., 2013; Itzhaki, 2014)?”
BackgroundThe Infectious Etiology of Alzheimer’s Disease
Sochocka, M., Zwolińska, K., & Leszek, J. (2017) · Current Neuropharmacology · doi:10.2174/1570159x15666170313122937 · Cited by 399
Therapies from Fucoidan; Multifunctional Marine Polymers
Fitton, J. H. (2011) · Marine Drugs · doi:10.3390/md9101731 · Cited by 392
Old Drugs as New Treatments for Neurodegenerative Diseases
Durães, F., Pinto, M., & Sousa, E. (2018) · Pharmaceuticals · doi:10.3390/ph11020044 · Cited by 343
Corroboration of a Major Role for Herpes Simplex Virus Type 1 in Alzheimer’s Disease
Itzhaki, R. F. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00324 · Cited by 256
Self-citation
Metadata
- Authors
- Wozniak, M. A., & Itzhaki, R. F.
- Venue
- Therapeutic Advances in Neurological Disorders
- Publisher
- SAGE Publications
- Published
- 2010-05
- Volume
- 3
- Issue
- 3
- Pages
- 141-152
- ISSN
- 1756-2856 (ISSN-L)
- 1756-2864
- OpenAlex
- W2109147078
- Cited by
- 59
- References
- 8
- FWCI
- 3.23
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Antiviral agents in Alzheimer’s disease: hope for the future? https://app.cochat.ai/papers/10.1177/1756285610370069
- The paper
- Wozniak, M. A., & Itzhaki, R. F. (2010). Antiviral agents in Alzheimer’s disease: hope for the future? Therapeutic Advances in Neurological Disorders. https://doi.org/10.1177/1756285610370069
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.